FLT3-ITD MRD dynamics predicted relapse risk and shaped response to gilteritinib maintenance in post-transplant AML.

This application note outlines a comprehensive workflow for MRD detection, using a next-generation sequencing (NGS) approach ...

The Philadelphia Eagles are Super Bowl champions, but there have still remained some residual concerns about head coach, Nick ...

Linda De Jesus, IDT Vice President and General Manager, Global Head of Commercial.

Cell-free DNA (cfDNA) analysis is transforming precision medicine, offering a non-invasive window into the body, particularly in the context of cancer. This journal collection, hosted by npj ...

Jeremy S. Abramson, MD, discusses pivotal advancements in DLBCL from the 2025 American Society of Clinical Oncology Annual ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

In a crowded cannabis edibles market, Area 52 has taken the lead as the benchmark for quality. In its extensive 2025 review, ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced new data that will be ...

New research presented by Noella Collado-Gisbert reveals that tracking residual disease kinetics in multiple myeloma predicts long-term survival and supports early treatment strategies to prevent ...

Understand the importance of analyzing all cell populations within a sample to avoid incomplete assessments and ensure accurate Minimal Residual Disease (MRD) analysis in Multiple Myeloma (MM).